Endogena therapeutics completes enrollment ahead of schedule in its phase 1/2a trial of ea-2353 for retinitis pigmentosa

San francisco and toronto and zÜrich, switzerland, may 04, 2023 (globe newswire) -- endogena therapeutics inc., a clinical-stage biotech company, is pleased to announce that it has completed patient enrollment ahead of schedule in its phase 1/2a trial of ea-2353 for the treatment of retinitis pigmentosa (rp).
EA Ratings Summary
EA Quant Ranking